

THIS LISTING OF CLAIMS REPLACES ALL PRIOR VERSIONS, AND LISTINGS,
OF CLAIMS IN THE APPLICATION.

Listing of Claims

C 1 (currently amended): A pharmaceutical composition, said composition comprising a therapeutically effective amount of a hypolipidemic compound of the formula R-COOH, or a salt or an ester or amide of such compound, where R designates a saturated or unsaturated alkyl chain of 10-24 carbon atoms, one or more of which may be replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, phenyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkynyl)-substituted phenyl, C₃-C₇ cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkynyl)-substituted C₃-C₇ cycloalkyl wherein said compound is capable of being endogenously converted to its respective coenzyme A thioester, RCOSCoA.

2 (original). A composition according to claim 1, wherein R is selected from the group consisting of ω -carboxyl, ω -hydroxyl boron, and ω -hydroxyl chains.

3 and 4 (canceled).

5 (original). A composition according to claim 1, where RCOOH is a saturated or unsaturated long chain fatty acid.

6 (original). A composition according to claim 5, where the fatty acid is chosen from:
Stearic (18:0) acid
Oleic (18:1) acid
Linolenic (18:2) acid

Linolenic (18:3) acid

Eicosapentaenic (20:5) acid

Docosahexaenic (22:6) acid

7 (original). A composition according to claim 1, wherein RCOOH is selected from the group consisting of:

1,16 Hexadecanedioic acid

1,18 Octadecanedioic acid

2,2,15,15-tetramethyl-hexadecane-1, 16-dioic acid

2,2,17,17-tetramethyl-octadecane-1, 18-dioic acid

3,3,14,14-tetramethyl-hexadecane-1, 16-dioic acid

3,3,16,16-tetramethyl-octadecane-1, 18-dioic acid

4,4,13,13-tetramethyl-hexadecane-1, 16-dioic acid and

4,4,15,15-tetramethyl-octadecane-1, 18-dioic acid

8 (currently amended). A composition according to claim 1, wherein RCOOH is selected from the group consisting of:

16- B(OH)₂-hexadecanoic acid

18- B(OH)₂-octadecanoic acid

16- B(OH)₂-2,2-dimethyl-hexadecanoic acid

18- B(OH)₂-2,2-dimethyl-octadecanoic acid

16- B(OH)₂-3,3-dimethyl-hexadecanoic acid

18- B(OH)₂-3,3-dimethyl-octadecanoic acid

16- B(OH)₂-4,4-dimethyl-hexadecanoic acid

18- B(OH)₂-4,4-dimethyl-octadecanoic acid

9 (original). A composition according to claim 1, wherein RCOOH is selected from the group consisting of:

16-hydroxy-hexadecanoic acid

18-hydroxy-octadecanoic acid

16-hydroxy-2,2-dimethyl-hexadecanoic acid

18-hydroxy-2,2-dimethyl-octadecanoic acid

16-hydroxy-3,3-dimethyl-hexadecanoic acid

18-hydroxy-3,3-dimethyl-octadecanoic acid

16-hydroxy-4,4-dimethyl-hexadecanoic acid

18-hydroxy-4,4-dimethyl-octadecanoic acid

10-20 (canceled).

21-31 (withdrawn).
